Thursday's Late Winners & Losers

Memory Pharmaceuticals (MEMY Quote) vaulted more than 21% in after-hours trading Thursday as the Montvale, N.J., biotech completed enrollment for a phase IIa clinical trial of Mem 1003, one of its proposed treatments for Alzheimer's disease. Memory Pharma expects top-line results to be in by the fourth quarter. Shares of the small-cap company were up 35 cents to $1.98.

Lubricant maker WD-40 (WDFC Quote) saw mounting profits for the quarter ended Feb. 28 that bested Wall Street estimates. The San Diego-based company earned $8.9 million, or 52 cents a share, on $79.3 million in sales, compared with 43-cent per-share profits last year. Analysts polled by Thomson Financial were seeking 46 cents a share on revenue of $78.3 million. Shares were rising $2.02, or 6.3%, to $33.91 in recent after-hours action.

Daktronics (DAKT Quote) slid 18% after lowering its outlook for the quarter ended April 28. The Brookings, S.D., maker of scoreboards and other visual display products now foresees profits of between 6 cents and 10 cents a share on revenue ranging between $101 million and $105 million. Prior estimates had pegged per-share earnings at 12 cents to 19 cents on sales of $106 million to $118 million. Shares were losing $5.06, to $22.85. ...